Brigatinib (BRG) in Crizotinib (CRZ)-Refractory ALK+ Non–Small Cell Lung Cancer (NSCLC): efficacy and safety results from ALTA, a pivotal randomized phase 2 Trial
| Autor: | Natasha B. Leighl, Howard West, M-J. Ahn, Frank G. Haluska, D.R. Camidge, W. Reichmann, L. Paz-Ares Rodriguez, Corey J. Langer, Egbert F. Smit, H. Groen, Scott N. Gettinger, Karen L. Reckamp, Dai Woo Kim, K. Holmskov Hansen, M. Tiseo, David Kerstein, Rudolf M. Huber, S-W. Kim, Maximilian Hochmair |
|---|---|
| Rok vydání: | 2016 |
| Předmět: |
0301 basic medicine
Oncology medicine.medical_specialty Pathology Brigatinib Crizotinib business.industry non-small cell lung cancer (NSCLC) Phases of clinical research Hematology medicine.disease 03 medical and health sciences 030104 developmental biology 0302 clinical medicine Refractory 030220 oncology & carcinogenesis Internal medicine Medicine business medicine.drug |
| Zdroj: | Annals of Oncology. 27:iv4 |
| ISSN: | 0923-7534 |
| DOI: | 10.1093/annonc/mdw332.04 |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|